Evidence map›Paper›PMID 28664300›Full record

ReviewInternational journal of clinical oncology2017

Brachytherapy in the treatment of breast cancer.

Xinna Deng, Haijiang Wu, Fei Gao, Ye Su, Qingxia Li, Shuzhen Liu, Jianhui Cai

Abstract readReview
PubMed Publisher
In one paragraph

Review in International journal of clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Role of Exosomes for Delivery of Chemotherapeutic Drugs.Critical reviews in therapeutic drug carrier systems · 2021
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Xinna DengDepartment of Oncology & Immunotherapy, Hebei General Hospital, Shijiazhuang, China.
Haijiang WuDepartment of Pathology, Hebei Medical University, Shijiazhuang, China.
Fei GaoDepartment of Oncology & Immunotherapy, Hebei General Hospital, Shijiazhuang, China.
Ye SuMathew Mailing Centre for Translational Transplantation Studies, Lawson Health Research Institute, London Health Sciences Centre, London, ON, Canada.
Qingxia LiDepartment of Oncology & Immunotherapy, Hebei General Hospital, Shijiazhuang, China.
Shuzhen LiuDepartment of Oncology & Immunotherapy, Hebei General Hospital, Shijiazhuang, China.
Jianhui CaiDepartment of Oncology & Immunotherapy, Hebei General Hospital, Shijiazhuang, China. jianhuicai2001@163.com.
Hebei General Hospital · CNHebei Medical University · CNLawson Health Research Institute · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brachytherapy is an important radio-therapeutic modality for a variety of malignancies, including prostate cancer, cervix cancer, breast cancer, vagina cancer, endometrium cancer, head and neck cancer, and many more. This technique has been shown to be an effective and safe non-pharmaceutical treatment with fewer serious complications and better outcome than other treatments for breast cancer. Every year, hundreds of thousands of patients around the world benefit from brachytherapy, which reliably delivers a relatively higher radiation dose to the intended target. However, the follow-up time, patient eligibility criteria, treatment strategy, and radiation doses used in published studies are somewhat inconsistent, making it difficult to strictly compare and evaluate the performance of the treatment. More rigorous studies are required to confirm the safety of this technique and to make outcome data more comparable. In this review, we focus on recent advances in breast brachytherapy techniques and provide an overview of outcomes, cosmetic outcome, toxicity, complications, and limitations of brachytherapy for the treatment of breast cancer. We also summarize the clinical outcomes and toxicity results in patients receiving or not receiving brachytherapy.

Indexed as

BrachytherapyBreast NeoplasmsFemaleHumansRadiotherapy DosageTreatment OutcomeBrachytherapyBreast cancerOutcomesRadiation therapy

Identifiers

PMID28664300
OpenAlexW2728753419

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.